Context Therapeutics

Context acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. $CNTX ir.contexttherapeutics.com/news-releases/…

Today @Context_Tx reported its full year 2025 operating and financial results. Our lead program, CTIM-76, is on track to present interim Phase 1a data in June 2026. Read our full press release here: ir.contexttherapeutics.com/news-releases/…

🚨Context Therapeutics ($CNTX) highlights CT-95 and CT-202 programs at #SITC2025 Meeting ✅ Both are potentially best-in-class ✅ Conditional activation at the tumor 👍 Complete tumor resolution in mice 👀View here: Publications — Context Therapeutics globenewswire.com/news-release/2…

🚨 Context Therapeutics $CNTX Q3 2025 Highlights:  ✅ CTIM-76 demonstrates encouraging antitumor activity and safety  ✅ CT-95 is approaching target dose levels   💰 $76.9M cash and cash equivalents as of Sept 30, 2025  ✅ Expected cash runway into 2027

Context Therapeutics is excited to share that we will be presenting at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting!   #SITC2025 #Immunotherapy #TCE ir.contexttherapeutics.com/news-releases/…

Our CEO, Martin Lehr, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference tomorrow, September 3rd. #cantor, #TCE, $CNTX

Context Therapeutics $CNTX Q2 2025 Highlights: ✅ CTIM-76 & CT-95 Phase 1 dose-escalation trials ongoing ✅ $83.5M cash and cash equivalents as of June 30, 2025 ✅ Expected cash runway into 2027 Read more here: ir.contexttherapeutics.com/news-and-event… #Biotech #Immunotherapy #CancerRes #TCE

$CNTX announces CTIM-76 Trial in Progress poster at #ASCO25 ✅Dosing Cohort 3 of Phase 1 trial ✅ CLDN6 x CD3 TCE for ovarian, endometrial & testicular cancers ✅Initial data expected 1H 2026 📍Poster: June 2, Hall A, 1:30 PM CDT 🔗 contexttherapeutics.com/ctim76 #Biotech

We’re excited to welcome Dr. Karen Chagin as Chief Medical Officer at $CNTX, effective June 9, 2025! With 10+ years leading T cell therapy development at Adaptimmune and Tmunity, she brings deep clinical expertise at a key time for Context. Read more: tinyurl.com/5c78te9f

🚨 Context Therapeutics $CNTX Q1 2025 Highlights: ✅ CTIM-76 & CT-95 in Phase 1 trials ✅ $89.4M cash and cash equivalents as of March 31, 2025 ✅ Expected cash runway into 2027 #Biotech #Immunotherapy #CancerResearch #TCellEngagers Read more here:ir.contexttherapeutics.com/news-releases/…

🚨 We’re excited to welcome Jennifer Dashnau, PhD, MBA as SVP of Technical Operations at Context Therapeutics! Welcome to the team, Jennifer! 👏 #Biotech #Leadership #Immunotherapy #TCellEngagers #ContextTherapeutics #Oncology #WomenInSTEM

The Context team presented preclinical and translational data for CT-95, our mesothelin-targeting T cell engager, at #AACR2025! View the poster here: contexttherapeutics.com/ct95 #Immunotherapy #Biotech $CNTX

📢 Context Therapeutics CEO Martin Lehr will join the T Cell Engagers panel at #AACR25! 🗓 Thursday, April 24 | 🕠 5:45–6:45 PM CT | 📍 Room W192 Moderated by Leerink Partners, the panel includes leaders from J&J, Zymeworks #Biotech #Immunotherapy #TCellEngagers

🚀Another big milestone for $CNTX: First patient dosed in Phase 1 clinical trial of CT-95, our mesothelin x CD3 T cell engaging bispecific antibody targeting solid tumors. CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 💡 #Immunotherapy

Join $CNTX at two premier events! Catch our presentation on Tuesday, April 8 at 10 AM ET during the Stifel Virtual Targeted Oncology Forum, and meet us at the 24th Annual Needham Virtual Healthcare Conference with 1x1 meetings on April 8th #Biotech

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors. Andy is the former EVP, Chief Strategy Officer of Horizon Pharma (acquired for $28Bn) and Senior Partner at Bain & Company.

Our CEO, Martin Lehr, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:00am ET.   #PiperSandler, #oncology, T cell engager

Our CEO, Martin Lehr, will present at the Stifel 2024 Healthcare Conference on November 19th at 1:50pm ET. Access the live webcast via: wsw.com/webcast/stifel…   #Stifel, #Oncology

Our CEO, Martin Lehr, will participate in a fireside chat at the 2024 UBS Healthcare Conference on November 13th at 2:45pm ET. Access the live webcast via: event.webcasts.com/starthere.jsp?…   #UBS, #Oncology

Context Therapeutics to Participate in UBS, Guggenheim, and Stifel Investor Conferences in November globenewswire.com/news-release/2…

Context Therapeutics ($CNTX) announces poster presentation featuring CTIM-76, a CLDN6xCD3 T cell engager, at #SITC2024 on November 9th.